文献速递糖尿病

强化血糖控制对2型糖尿病患者微血管结局的影响:基于随机对照试验个体参与者数据的Meta分析

Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials.
PubMed 文献 · Lancet Diabetes Endocrinol · 2017-03-30

该Meta分析纳入ACCORD、ADVANCE、UKPDS和VADT四项试验共27049例2型糖尿病患者,比较强化与较弱血糖控制对微血管事件的影响。强化控糖使肾脏事件风险降低20%(HR 0.80),眼事件风险降低13%(HR 0.87),但神经事件风险未降低(HR 0.98)。

要点

  • 强化控糖使肾脏事件风险降低20%(HR 0.80,95%CI 0.72-0.88;p<0.0001)。
  • 强化控糖使眼事件风险降低13%(HR 0.87,95%CI 0.76-1.00;p=0.04)。
  • 强化控糖未降低神经事件风险(HR 0.98,95%CI 0.87-1.09;p=0.68)。

核心结论

  • 强化血糖控制持续约5年可降低肾脏事件和眼事件风险,但未降低神经事件风险。
  • 降低血糖对预防2型糖尿病成人长期微血管并发症仍然重要。

研究设计与样本

  • 研究类型为Meta分析,获取大型随机对照试验的个体参与者数据。
  • 纳入标准为每组随访至少1000患者年且随机治疗平均随访至少2年的强化与较弱血糖控制对比试验。
  • 共纳入ACCORD、ADVANCE、UKPDS和VADT四项试验,合计27049例参与者。
  • 预设主要结局为肾脏事件、眼事件和神经事件的复合终点,采用随机效应模型计算总效应估计。

主要发现

  • 随访中位5.0年(IQR 4.5-5.0),记录肾脏事件1626例、眼事件795例、神经事件7598例。
  • 与较弱血糖控制相比,强化血糖控制使随访结束时平均HbA1c绝对差异为-0.90%(95%CI -1.22至-0.58)。
  • 强化控糖使肾脏事件相对风险降低20%(HR 0.80,95%CI 0.72-0.88;p<0.0001)。
  • 强化控糖使眼事件相对风险降低13%(HR 0.87,95%CI 0.76-1.00;p=0.04)。
  • 强化控糖未降低神经事件风险(HR 0.98,95%CI 0.87-1.09;p=0.68)。

关键数值与推荐

  • 肾脏事件复合终点包括终末期肾病、肾脏死亡、估算肾小球滤过率<30 mL/min per 1·73m2或显性糖尿病肾病的发生。
  • 眼事件复合终点包括需视网膜光凝治疗或玻璃体切除术、增殖性视网膜病变发生或糖尿病视网膜病变进展。
  • 神经事件复合终点包括振动觉、踝反射或轻触觉的新发丧失。

临床怎么用

  • 原文未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intensive glucose control is understood to prevent complications in adults with type 2 diabetes. We aimed to more precisely estimate the effects of more intensive glucose control, compared with less intensive glucose control, on the risk of microvascular events. METHODS: In this meta-analysis, we obtained de-identified individual participant data from large-scale randomised controlled trials assessing the effects of more intensive glucose control versus less intensive glucose control in adults with type 2 diabetes, with at least 1000 patient-years of follow-up in each treatment group and a minimum of 2 years average follow-up on randomised treatment. The prespecified and standardised primary outcomes were kidney events (a composite of end-stage kidney disease, renal death, development of an estimated glomerular filtration rate <30 mL/min per 1·73m2, or development of overt diabetic nephropathy), eye events (a composite of requirement for retinal photocoagulation therapy or vitrectomy, development of proliferative retinopathy, or progression of diabetic retinopathy), and nerve events (a composite of new loss of vibratory sensation, ankle reflexes, or light touch). We used a random-effects model to calculate overall estimates of effect. FINDINGS: We included four trials (ACCORD, ADVANCE, UKPDS, and VADT) with 27 049 participants. 1626 kidney events, 795 eye events, and 7598 nerve events were recorded during the follow-up period (median 5·0 years, IQR 4·5-5·0). Compared with less intensive glucose control, more intensive glucose control resulted in an absolute difference of -0·90% (95% CI -1·22 to -0·58) in mean HbA1c at completion of follow-up. The relative risk was reduced by 20% for kidney events (hazard ratio 0·80, 95% CI 0·72 to 0·88; p<0·0001) and by 13% for eye events (0·87, 0·76 to 1·00; p=0·04), but was not reduced for nerve events (0·98, 0·87 to 1·09; p=0·68). INTERPRETATION: More intensive glucose control over 5 years reduced both kidney and eye events. Glucose lowering remains important for the prevention of long-term microvascular complications in adults with type 2 diabetes. FUNDING: None.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017. PMID: 28365411. doi:10.1016/S2213-8587(17)30104-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。